In vivo primary induction of virus-specific CTL by immunization with 9-mer synthetic peptides.
Identifieur interne : 002806 ( PubMed/Checkpoint ); précédent : 002805; suivant : 002807In vivo primary induction of virus-specific CTL by immunization with 9-mer synthetic peptides.
Auteurs : X. Zhou [Suède] ; L. Berg ; U M Motal ; M. JondalSource :
- Journal of immunological methods [ 0022-1759 ] ; 1992.
Descripteurs français
- KwdFr :
- Animaux, Antigènes d'histocompatibilité de classe I (immunologie), Cytotoxicité immunologique, Données de séquences moléculaires, Femelle, Immunisation, Lymphocytes T cytotoxiques (immunologie), Peptides (immunologie), Souris, Souris de lignée C57BL, Séquence d'acides aminés, Virus de la grippe A (immunologie).
- MESH :
English descriptors
- KwdEn :
- MESH :
- chemical , immunology : Histocompatibility Antigens Class I, Peptides.
- immunology : Influenza A virus, T-Lymphocytes, Cytotoxic.
- Amino Acid Sequence, Animals, Cytotoxicity, Immunologic, Female, Immunization, Mice, Mice, Inbred C57BL, Molecular Sequence Data.
Abstract
A primary cytotoxic T lymphocyte (CTL) response in vivo requires antigen presentation by cytosolic processing and can not in general be obtained by vaccination with soluble proteins. In the present work we have found that vaccination of mice with pre-processed synthetic peptides, corresponding to endogenous 9-mers produced in influenza A virus-infected cells, resulted in strong primary CTL responses. The generated CTL efficiently killed virus-infected target cells with preference for viral strains having the identical amino acid sequences to the peptides used for immunization. The optimal conditions for a primary in vivo CTL response was obtained with 100 micrograms peptide dissolved in incomplete Freund's adjuvant and injected s.c. at the base of tail. Spleen cells which had been primed 7-10 days earlier were restimulated for 5 days in vitro, using an optimal low peptide concentration (0.05 microM) and tested against virus-infected and peptide-treated target cells. The peptide-induced CTL were major histocompatibility complex class I restricted and CD8 positive.
DOI: 10.1016/0022-1759(92)90322-k
PubMed: 1517589
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:1517589Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">In vivo primary induction of virus-specific CTL by immunization with 9-mer synthetic peptides.</title><author><name sortKey="Zhou, X" sort="Zhou, X" uniqKey="Zhou X" first="X" last="Zhou">X. Zhou</name><affiliation wicri:level="3"><nlm:affiliation>Department of Immunology, Karolinska Institute, Stockholm, Sweden.</nlm:affiliation><country xml:lang="fr">Suède</country><wicri:regionArea>Department of Immunology, Karolinska Institute, Stockholm</wicri:regionArea><placeName><settlement type="city">Stockholm</settlement><region nuts="2">Svealand</region></placeName></affiliation></author><author><name sortKey="Berg, L" sort="Berg, L" uniqKey="Berg L" first="L" last="Berg">L. Berg</name></author><author><name sortKey="Motal, U M" sort="Motal, U M" uniqKey="Motal U" first="U M" last="Motal">U M Motal</name></author><author><name sortKey="Jondal, M" sort="Jondal, M" uniqKey="Jondal M" first="M" last="Jondal">M. Jondal</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1992">1992</date><idno type="RBID">pubmed:1517589</idno><idno type="pmid">1517589</idno><idno type="doi">10.1016/0022-1759(92)90322-k</idno><idno type="wicri:Area/PubMed/Corpus">002949</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002949</idno><idno type="wicri:Area/PubMed/Curation">002949</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002949</idno><idno type="wicri:Area/PubMed/Checkpoint">002806</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002806</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">In vivo primary induction of virus-specific CTL by immunization with 9-mer synthetic peptides.</title><author><name sortKey="Zhou, X" sort="Zhou, X" uniqKey="Zhou X" first="X" last="Zhou">X. Zhou</name><affiliation wicri:level="3"><nlm:affiliation>Department of Immunology, Karolinska Institute, Stockholm, Sweden.</nlm:affiliation><country xml:lang="fr">Suède</country><wicri:regionArea>Department of Immunology, Karolinska Institute, Stockholm</wicri:regionArea><placeName><settlement type="city">Stockholm</settlement><region nuts="2">Svealand</region></placeName></affiliation></author><author><name sortKey="Berg, L" sort="Berg, L" uniqKey="Berg L" first="L" last="Berg">L. Berg</name></author><author><name sortKey="Motal, U M" sort="Motal, U M" uniqKey="Motal U" first="U M" last="Motal">U M Motal</name></author><author><name sortKey="Jondal, M" sort="Jondal, M" uniqKey="Jondal M" first="M" last="Jondal">M. Jondal</name></author></analytic><series><title level="j">Journal of immunological methods</title><idno type="ISSN">0022-1759</idno><imprint><date when="1992" type="published">1992</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Amino Acid Sequence</term><term>Animals</term><term>Cytotoxicity, Immunologic</term><term>Female</term><term>Histocompatibility Antigens Class I (immunology)</term><term>Immunization</term><term>Influenza A virus (immunology)</term><term>Mice</term><term>Mice, Inbred C57BL</term><term>Molecular Sequence Data</term><term>Peptides (immunology)</term><term>T-Lymphocytes, Cytotoxic (immunology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term><term>Antigènes d'histocompatibilité de classe I (immunologie)</term><term>Cytotoxicité immunologique</term><term>Données de séquences moléculaires</term><term>Femelle</term><term>Immunisation</term><term>Lymphocytes T cytotoxiques (immunologie)</term><term>Peptides (immunologie)</term><term>Souris</term><term>Souris de lignée C57BL</term><term>Séquence d'acides aminés</term><term>Virus de la grippe A (immunologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Histocompatibility Antigens Class I</term><term>Peptides</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Antigènes d'histocompatibilité de classe I</term><term>Lymphocytes T cytotoxiques</term><term>Peptides</term><term>Virus de la grippe A</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Influenza A virus</term><term>T-Lymphocytes, Cytotoxic</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Amino Acid Sequence</term><term>Animals</term><term>Cytotoxicity, Immunologic</term><term>Female</term><term>Immunization</term><term>Mice</term><term>Mice, Inbred C57BL</term><term>Molecular Sequence Data</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Cytotoxicité immunologique</term><term>Données de séquences moléculaires</term><term>Femelle</term><term>Immunisation</term><term>Souris</term><term>Souris de lignée C57BL</term><term>Séquence d'acides aminés</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">A primary cytotoxic T lymphocyte (CTL) response in vivo requires antigen presentation by cytosolic processing and can not in general be obtained by vaccination with soluble proteins. In the present work we have found that vaccination of mice with pre-processed synthetic peptides, corresponding to endogenous 9-mers produced in influenza A virus-infected cells, resulted in strong primary CTL responses. The generated CTL efficiently killed virus-infected target cells with preference for viral strains having the identical amino acid sequences to the peptides used for immunization. The optimal conditions for a primary in vivo CTL response was obtained with 100 micrograms peptide dissolved in incomplete Freund's adjuvant and injected s.c. at the base of tail. Spleen cells which had been primed 7-10 days earlier were restimulated for 5 days in vitro, using an optimal low peptide concentration (0.05 microM) and tested against virus-infected and peptide-treated target cells. The peptide-induced CTL were major histocompatibility complex class I restricted and CD8 positive.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">1517589</PMID><DateCompleted><Year>1992</Year><Month>10</Month><Day>06</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0022-1759</ISSN><JournalIssue CitedMedium="Print"><Volume>153</Volume><Issue>1-2</Issue><PubDate><Year>1992</Year><Month>Aug</Month><Day>30</Day></PubDate></JournalIssue><Title>Journal of immunological methods</Title><ISOAbbreviation>J. Immunol. Methods</ISOAbbreviation></Journal><ArticleTitle>In vivo primary induction of virus-specific CTL by immunization with 9-mer synthetic peptides.</ArticleTitle><Pagination><MedlinePgn>193-200</MedlinePgn></Pagination><Abstract><AbstractText>A primary cytotoxic T lymphocyte (CTL) response in vivo requires antigen presentation by cytosolic processing and can not in general be obtained by vaccination with soluble proteins. In the present work we have found that vaccination of mice with pre-processed synthetic peptides, corresponding to endogenous 9-mers produced in influenza A virus-infected cells, resulted in strong primary CTL responses. The generated CTL efficiently killed virus-infected target cells with preference for viral strains having the identical amino acid sequences to the peptides used for immunization. The optimal conditions for a primary in vivo CTL response was obtained with 100 micrograms peptide dissolved in incomplete Freund's adjuvant and injected s.c. at the base of tail. Spleen cells which had been primed 7-10 days earlier were restimulated for 5 days in vitro, using an optimal low peptide concentration (0.05 microM) and tested against virus-infected and peptide-treated target cells. The peptide-induced CTL were major histocompatibility complex class I restricted and CD8 positive.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>X</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Immunology, Karolinska Institute, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berg</LastName><ForeName>L</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Motal</LastName><ForeName>U M</ForeName><Initials>UM</Initials></Author><Author ValidYN="Y"><LastName>Jondal</LastName><ForeName>M</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Immunol Methods</MedlineTA><NlmUniqueID>1305440</NlmUniqueID><ISSNLinking>0022-1759</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015395">Histocompatibility Antigens Class I</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010455">Peptides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003602" MajorTopicYN="N">Cytotoxicity, Immunologic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015395" MajorTopicYN="N">Histocompatibility Antigens Class I</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007114" MajorTopicYN="N">Immunization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009980" MajorTopicYN="N">Influenza A virus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010455" MajorTopicYN="N">Peptides</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013602" MajorTopicYN="N">T-Lymphocytes, Cytotoxic</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1992</Year><Month>8</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1992</Year><Month>8</Month><Day>30</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1992</Year><Month>8</Month><Day>30</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">1517589</ArticleId><ArticleId IdType="pii">0022-1759(92)90322-K</ArticleId><ArticleId IdType="doi">10.1016/0022-1759(92)90322-k</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Suède</li></country><region><li>Svealand</li></region><settlement><li>Stockholm</li></settlement></list><tree><noCountry><name sortKey="Berg, L" sort="Berg, L" uniqKey="Berg L" first="L" last="Berg">L. Berg</name><name sortKey="Jondal, M" sort="Jondal, M" uniqKey="Jondal M" first="M" last="Jondal">M. Jondal</name><name sortKey="Motal, U M" sort="Motal, U M" uniqKey="Motal U" first="U M" last="Motal">U M Motal</name></noCountry><country name="Suède"><region name="Svealand"><name sortKey="Zhou, X" sort="Zhou, X" uniqKey="Zhou X" first="X" last="Zhou">X. Zhou</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002806 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 002806 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:1517589
|texte= In vivo primary induction of virus-specific CTL by immunization with 9-mer synthetic peptides.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:1517589" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a MersV1
| This area was generated with Dilib version V0.6.33. |  |